EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The prevention of rifampicin resistance with pyrazinamide


Revue des Maladies Respiratoires 2(4): 205-208
The prevention of rifampicin resistance with pyrazinamide
The capacity of pyrazinamide (PZA) to prevent the selection of rifampicin (RMP) resistant mutants were tested by the intravenous inoculation of 160 mice with 2 .times. 106 c.f.u. [colony forming unit] of Mycobacterium tuberculosis, and two weeks later, the treatment of the mice either with 10 mg/kg/day RMP alone or with RMP + PZA 150 mg/kg/day. After three months of treatment, lungs and spleen were culture positive in respectively 95% and 90% of the mice treated with RMP alone and in 37% and 24% of the mice treated by RMP + PZA (p < 10-5). The strains isolated from lungs and spleen were resistant to rifampicin in respectively 87% and 75% of the mice treated with RMP alone and in none of those treated with RMP + PZA.


Accession: 006740640



Related references

Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse. Revue des Maladies Respiratoires 2(4): 205-208, 1985

Prevention of resistance of rifampicin by means of pyrazinamide in experimental tuberculosis in the mouse. Revue des Maladies Respiratoires 2(2): 111, 1985

Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. International Journal of Clinical Pharmacology and Therapeutics 40(10): 474-481, 2002

Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. International Journal of Tuberculosis and Lung Disease 19(6): 679-684, 2016

Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351(9118): 1813-1813, 1998

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351(9105): 786-792, 1998

Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. South African Medical Journal 86(2): 155-158, 1996

Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. Journal of Antimicrobial ChemoTherapy 58(3): 689-692, 2006

Clinical evaluation of rifampicin in advanced pulmonary tuberculosis resistant to conventional antituberculosis drugs. Combination therapy with rifampicin and pyrazinamide. Kekkaku 46(7): 259-264, 1971

Criteria of resistance of some antibiotics and chemotherapeutics for strains of Mycobacterium tuberculosis isolated in Czechoslovakia. Cycloserin, ethionamide, pyrazinamide, rifampicin, and ethambutol. Casopis Lekaru Ceskych 118(8): 240-245, 1979